Masafumi Nishino - Concepedia

Author

Masafumi Nishino

Hamamatsu University School of Medicine

Also Known As

M Nishino, M. NISHINO, M. Nishino, Machiko NISHINO, Masafumi NISHINO, Masafumi Nishino, Nishino, Masafumi

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Hamamatsu University School of Medicine JA Shizuoka Koseiren ENSHU hospital Center for Clinical Research (United States)Hamamatsu University Oita University

About

Masafumi Nishino is an author at Hamamatsu University School of Medicine specializing in medicine, gastroenterology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	258
2	Health Sciences	2	2	25
3	Public Health	2	2	41
4	Epidemiology	2	2	41
5	Biochemistry	1	1	13

Masafumi Nishino

Publications

960

Citations

H-Index

Page 1

	Year	Citations
Evidence that the Degree and Duration of Acid Suppression are Related to <i>Helicobacter pylori</i> Eradication by Triple Therapy Mitsushige Sugimoto, Takahisa Furuta, Naohito Shirai, Helicobacter	2007	147
Polydom Is an Extracellular Matrix Protein Involved in Lymphatic Vessel Remodeling Nanami Morooka, Sugiko Futaki, Masafumi Nishino, Circulation Research	2017	95
Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy Naohito Shirai, Mitsushige Sugimoto, Chise Kodaira, European Journal of Clinical Pharmacology Helicobacter Pylori InfectionAntibioticsStandard Triple TherapyAntimicrobial ChemotherapyDual Therapy	2007	90
Rabeprazole 10 mg q.d.s. decreases 24‐h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming <scp>CYP</scp>2<scp>C</scp>19 genotype Mitsushige Sugimoto, Naohito Shirai, Masafumi Nishino, Alimentary Pharmacology & Therapeutics	2012	59
Effect of<i>MDR1</i>C3435T polymorphism on cure rates of<i>Helicobacter pylori</i>infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to<i>CYP </i>2C19 genotypes and 23S rRNA genotypes of<i>H. pylori</i> Takahisa Furuta, Mitsushige Sugimoto, Naohito Shirai, Alimentary Pharmacology & Therapeutics	2007	46
Sitafloxacin‐based third‐line rescue regimens for <i><scp>H</scp>elicobacter pylori</i> infection in <scp>J</scp>apan Takahisa Furuta, Mitsushige Sugimoto, Chise Kodaira, Journal of Gastroenterology and Hepatology	2013	40
Resistance of <i>Helicobacter pylori</i> to quinolones and clarithromycin assessed by genetic testing in Japan Mihoko Yamade, Mitsushige Sugimoto, Takahiro Uotani, Journal of Gastroenterology and Hepatology	2011	38
Modified allele‐specific primer–polymerase chain reaction method for analysis of susceptibility of <i>Helicobacter pylori</i> strains to clarithromycin Takahisa Furuta, Yoshihiro Soya, Mitsushige Sugimoto, Journal of Gastroenterology and Hepatology	2007	36
CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole Takahisa Furuta, Mitsushige Sugimoto, Chise Kodaira, European Journal of Clinical Pharmacology Cyp2c19 GenotypeUrologyLow-dose LansoprazoleGastroenterologyMaintenance Therapy	2009	32
Relationship Between Low-Dose Aspirin-Induced Gastric Mucosal Injury and Intragastric pH in Healthy Volunteers Masafumi Nishino, Mitsushige Sugimoto, Chise Kodaira, Digestive Diseases and Sciences	2009	32

Page 1